[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnant-woman\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnant-woman":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642298","bone-management-in-pregnancy-outcomes-in-epilepsy-100642298",false,"NCT07651709","Bone Management in Pregnancy Outcomes in Epilepsy","Bone Health Management on Pregnancy Outcomes in Women With Epilepsy: Randomized Study","Inclusion Criteria:\n\n* Diagnosis of focal or generalized epilepsy as defined by the International League Against Epilepsy.\n* Women of childbearing age, aged ≥18 years, planning pregnancy or in early pregnancy (≤16 weeks gestation, confirmed by last menstrual period or ultrasound) - single pregnancy.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Pre-existing conditions affecting bone metabolism: primary hyperparathyroidism, Paget's disease, multiple myeloma, chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin), cirrhosis (Child-Pugh B\u002FC), or untreated hyper\u002Fhypothyroidism.\n* History of metabolic complications: hypercalcemia (serum Ca²⁺ \\>10.5 mg\u002FdL), nephrolithiasis, or granulomatous diseases.\n* Recent\u002Fcurrent use of bone-modifying drugs: bisphosphonates, glucocorticoids (≥5 mg\u002Fday prednisone equivalent for \\>1 month), or loop diuretics within the past year.\n* Ultrasound shows fetal malformation.\n* Presence of other severe systemic diseases deemed unsuitable for study participation by the investigator.",true,"FEMALE","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is aimed to evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE.",[27,28,29],"Epilepsy","Pregnant Woman","Bone Health",[31,32],"epilepsy","pregnancy","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2035-01",{"name":43,"class":44},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100566340","phase-4-levothyroxine-intervention-in-pregnant-women-with-tsh-25-miul-upper-limit-of-reference-range-and-negative-thyroid-peroxidase-antibody-100566340","NCT06653907","Levothyroxine Intervention in Pregnant Women with TSH （2.5 MIU\u002FL-upper Limit of Reference Range） and Negative Thyroid Peroxidase Antibody","Randomized Control Study of Levothyroxine Intervention in Pregnant Women with Thyroid Stimulating Hormone Between 2.5 MIU\u002FL and Upper Limit of Reference Range and Negative Thyroid Peroxidase Antibody","LIGHT","Inclusion Criteria:\n\n1. Women of childbearing age（18-45 years old）, natural pregnancy, singleton pregnancy.\n2. Measure thyroid related indexes within 8 weeks of pregnancy: TSH 2.5mIU\u002FL-ULRR, FT4 is normal and TPOAb negativity.\n3. Willing to sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of recurrent miscarriage (≥3 times).\n2. Assisted reproduction (artificial insemination, in vitro fertilization and embryo transfer);\n3. Suffer from diseases that seriously affect pregnancy outcome, including hypertension, diabetes, heart disease, liver and kidney dysfunction, etc.\n4. Failure of vital organs.\n5. Except autoimmune thyroid disease，suffer from other autoimmune diseases.\n6. Thyroid diseases (including hyperthyroidism, thyroid cancer, thyroid amyloidosis and other extensive intrathyroidal diseases, current subacute thyroiditis, iodine-deficiency endemic goiter, thyroidectomy or 131I treatment, previous thyroid Ultrasound prompts diffuse thyroid disease, etc.).\n7. Use of thyroid-related drugs (lithium carbonate, thioureas, sulfonamides, sodium para-amino salicylate, potassium perchlorate, phenylbutazone, sulfate, tyrosine kinase inhibitor, etc.) during screening and affect thyroid Functional testing drugs. (Including glucocorticoids, metoclopramide, propranolol, amiodarone, sodium valproate, etc.)\n8. Secondary hypothyroidism or central hypothyroidism. (Including pituitary tumors, surgery, radiotherapy, lymphocytic hypophysitis, etc.)\n9. L-T4 allergy.\n10. Unwilling to sign an informed consent.\n11. Other clinicians judged that they are not suitable to participate in the study.","45 Years",{"count":56,"type":21},400,[58],"PHASE4","The goal of this clinical trial is to learn if levothyroxine (L-T4) works to treat pregnant women with TSH 2.5 mIU\u002FL-the upper limit of reference range (ULRR) of pregnancy and TPOAb-negative. It will also learn about the safety of L-T4. The main quesitons the investigator want to answer are:\n\n* Will L-T4 reduce miscarriage rates and have an impact on pregnancy complications in pregnant participants?\n* What medical issues do participants have when taking L-T4 during pregnancy? -Investigators will compare L-T4 with placebo (a substance with a similar appearance without medication) to see if L-T4 could reduce miscarriage rates\n\nParticipants should:\n\n* Take L-T4 or placebo during the whole pregnancy.\n* Visit the hospital once every 6-8 weeks during pregnancy for checkups and tests\n* Keep a diary of their pregncny complications and daily record of L-T4 or placebo intake.\n* Visit the hospital for examination 42 days postpartum for checkups and follow up by phone at 6 and 12 months postpartum.",[61,28,62],"Thyroid Abnormalities","Pregnancy Outcomes",[64,65,66,67,68],"TSH","TPOAb","pregnant women","levothyroxine","outcome","NOT_YET_RECRUITING","2024-10-21",{"date":72,"type":37},"2024-10-23",{"date":74,"type":21},"2024-10-25",{"date":76,"type":21},"2027-10-31",{"name":78,"class":44},"Yang ZHANG",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100561048","physical-activity-and-sedentary-behavior-during-pregnancy-100561048","NCT06585085","Physical Activity and Sedentary Behavior During Pregnancy","Care Pathway Organization in Order to Increase Physical Activity Levels and Limit Sedentary Behavior During Pregnancy: a Randomized Controlled Trial","PREGMOUV","Inclusion Criteria:\n\n* Pregnant women of more of 18 years and who are being monitored for pregnancy in the Clermont-Ferrand metropolitan area,\n* Planned to give birth in a maternity unit localized in Clermont-Ferrand metropolitan area (CHU Estaing or Clinique de la Chataigneraie),\n* Agreeing to be randomized, to follow the physical activity program offered in the Clermont-Ferrand metropolitan area, and to follow up as part of the study,\n* Able to give informed consent to participate in the research,\n* Affiliated to a social security scheme\n* And between 14+0d and 21+6d weeks of gestation.\n\nNon inclusion Criteria:\n\n* Women under guardianship, curators, deprived of liberty or under court protection,\n* With a history of recurrent miscarriage,\n* Presenting a multiple pregnancy,\n* Hemoglobinemia \\\u003C9g\u002FdL or symptomatic anemia,\n* Presenting eating disorders or a BMI ≤ 18.5 or a BMI ≥ 40,\n* With orthopedic limitations,\n* Presenting cardiovascular or pulmonary disease,\n* Uncontrolled thyroid disease,\n* Presenting a high level of smoking,\n* With significant health problems,\n* Premature rupture of membranes,\n* Premature labor during this pregnancy or a history of at least 2 premature births,\n* Persistent vaginal bleeding,\n* Cervical incompetence,\n* Evidence of intrauterine growth restriction,\n* Uncontrolled epilepsy,\n* Diabetes (previous or gestational, diagnosed in the 1st trimester) or chronic hypertension,\n* Or having a planned home birth.",{"count":88,"type":21},630,[24],"Our main objective is to evaluate the intervention that best enables women's adherence to physical activity (PA).\n\nOur hypothesis is that identifying types of interventions suitable for pregnant women (in-person PA sessions, videoconferences or mixed format) could help improve their PA level and simultaneously reduce their sedentary behavior (SB).",[28],[93,94,95],"physical activity","sedentary behaviour","care pathway","2024-09-23",{"date":98,"type":37},"2024-09-24",{"date":100,"type":37},"2024-09-10",{"date":102,"type":21},"2027-10",{"name":104,"class":44},"University Hospital, Clermont-Ferrand"]